Driven by the growth in atrial fibrillation (AF) prevalent cases across Europe, demand is increasing for more advanced electrophysiology (EP) technologies, supported by improved clinical decision-making and increased hospital budgets. Patient needs have been historically underserved, but increased budgets among mostly public hospitals have driven high single-digit growth in new EP system installations. As a result, Europe’s EP lab systems market is forecast to expand at a 6% compound annual growth rate (CAGR) between 2025 and 2036, with momentum also supported by recent regulatory progress, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “Electrophysiology Lab Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036” reveals that Europe accounted for 28% of the global EP lab systems market in 2025.

In a new development for the market, Boston Scientific has recently secured an expanded CE Mark for its FARAPULSE Pulsed Field Ablation (PFA) System, which broadens the labeled indication to include patients with persistent atrial fibrillation (AF), and this is expected to facilitate wider uptake of PFA across major European markets. Pulsed field ablation systems utilize non-thermal energy technology that selectively targets cardiac tissue responsible for abnormal electrical signals while minimizing damage to surrounding structures.

Anindita Ghosh, Medical Devices Analyst at GlobalData, comments: “Europe is witnessing an expanding use of advanced EP technologies, with a particularly strong uptake of pulsed field ablation in high-volume centers. PFA use is expanding beyond early adopters as clinical and real-world evidence supports a favorable safety profile and competitive efficiency for AF, especially for pulmonary vein isolation, although adoption remains uneven across countries due to differences in reimbursement, training, and capital constraints.”

Adoption of PFA technologies is also supported by clinical findings from the ADVANTAGE AF trial, which evaluated the safety and effectiveness of the FARAPULSE system in patients with persistent AF. The study reported favorable outcomes, including high rates of freedom from atrial arrhythmias at 12 months and a strong safety profile. Coupled with advancements in EP technologies and increasing physician familiarity with PFA, these developments are expected to drive wider adoption of next-generation ablation systems and improve treatment outcomes for patients with atrial fibrillation.

Ghosh concludes: “Innovations in cardiac EP technologies are improving arrhythmia treatment pathways across European markets. While advanced ablation systems are enhancing procedural efficiency, the long-term durability and clinical outcomes of newer technologies are still being established, highlighting the need for continuous evaluation.”